KERYX BIOPHARMACEUTICALS INC Form 8-K July 31, 2013

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

## FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 31, 2013

## Keryx Biopharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction

000-30929 (Commission 13-4087132 (IRS Employer

of Incorporation) File Number) Identification No.)


750 Lexington Avenue

New York, New York 10022

(Address of Principal Executive Offices)

(212) 531-5965

(Registrant s telephone number, including area code)



- Written communications pursuant to Rule 425 under the Securities Act.
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
- " Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

#### Item 2.02. Results of Operations and Financial Condition.

On July 31, 2013, Keryx Biopharmaceuticals, Inc. (Keryx) issued a press release announcing its results of operations for the second quarter ended June 30, 2013. Keryx also announced that on Thursday, August 1, 2013 at 8:30am EDT, Keryx will host an investor conference call to discuss the Company s second quarter financial results and provide a business outlook for the remainder of 2013. A copy of such press release is being furnished as Exhibit 99.1 to this report.

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Keryx Biopharmaceuticals, Inc.** (Registrant)

Date: July 31, 2013

By: /s/ James F. Oliviero James F. Oliviero, CFA Chief Financial Officer

#### INDEX TO EXHIBITS

Exhibit

Number Description

99.1 Press Release dated July 31, 2013.